Stock NGNE NEUROGENE INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Neurogene Inc.

Equities

NGNE

US64135M1053

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
37.6 USD +10.10% Intraday chart for Neurogene Inc. +17.10% +94.01%
May. 10 Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 07 Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome During Asgct Annual Meeting CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
AQ
Neurogene: Q1 Earnings Snapshot
AQ
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
BU
Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Neurogene : ASGCT NGN-401 Clinical Safety Poster
PU
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
BU
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome During Asgct Annual Meeting
CI
Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target
MT
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
BU
North American Morning Briefing : Stocks Struggle After New Records
DJ
William Blair Initiates Neurogene With Outperform Rating
MT
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
BU
Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Inflation -2-
DJ
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
BU
Neurogene Inc. Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
CI
Neurogene to Participate in Upcoming Investor Conferences
BU
Neurogene Inc. Appoints Donna Cochener as Senior Vice President, General Counsel
CI
Neurogene Inc. Appoints Julie Jordan as Chief Medical Officer
CI
Neurogene Names Julie Jordan as Chief Medical Officer
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NGNE Stock
  4. News Neurogene Inc.